A vaccine containing fixed virus particles, wherein the fixed virus particles are obtained by treating original virus particles or corresponding inactivated virus particles in a suspension with a fixative, wherein the fixative comprises glutaraldehyde or 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, wherein the virus particles comprise influenza virus particles or Japanese encephalitis virus particles, wherein the concentration of the glutaraldehyde is 0.001 to 0.06 w/v% based on the total amount of the suspension and the fixative, wherein the concentration of the 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride is 0.05 to 1500 mM based on the total amount of the suspension and fixative, wherein the content of a lipid component in the fixed virus particles is equivalent to the content of the lipid component in the original virus particles and wherein: (a) a summed fever response of three rabbits to the fixed virus particles in a pyrogen test is less than 80% based on a summed fever response of three rabbits to original virus particles of the fixed virus particles or corresponding inactivated virus particles; or (b) an amount of an inflammatory cytokine produced from human peripheral blood mononuclear cells stimulated with the fixed virus particles is less than 80% based on an amount of the inflammatory cytokine produced from human peripheral blood mononuclear cells stimulated with original virus particles of the fixed virus particles or corresponding inactivated virus particles. wherein the fixed virus particles are obtained by treating original virus particles or corresponding inactivated virus particles in a suspension with a fixative, wherein the fixative comprises glutaraldehyde or 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride, wherein the virus particles comprise influenza virus particles or Japanese encephalitis virus particles, wherein the concentration of the glutaraldehyde is 0.001 to 0.06 w/v% based on the total amount of the suspension and the fixative, wherein the concentration of the 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride is 0.05 to 1500 mM based on the total amount of the suspension and fixative, wherein the content of a lipid component in the fixed virus particles is equivalent to the content of the lipid component in the original virus particles and wherein: (a) a summed fever response of three rabbits to the fixed virus particles in a pyrogen test is less than 80% based on a summed fever response of three rabbits to original virus particles of the fixed virus particles or corresponding inactivated virus particles; or (b) an amount of an inflammatory cytokine produced from human peripheral blood mononuclear cells stimulated with the fixed virus particles is less than 80% based on an amount of the inflammatory cytokine produced from human peripheral blood mononuclear cells stimulated with original virus particles of the fixed virus particles or corresponding inactivated virus particles. (a) a summed fever response of three rabbits to the fixed virus particles in a pyrogen test is less than 80% based on a summed fever response of three rabbits to original virus particles of the fixed virus particles or corresponding inactivated virus particles; or (b) an amount of an inflammatory cytokine produced from human peripheral blood mononuclear cells stimulated with the fixed virus particles is less than 80% based on an amount of the inflammatory cytokine produced from human peripheral blood mononuclear cells stimulated with original virus particles of the fixed virus particles or corresponding inactivated virus particles.